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Vascular calciﬁcations produce a high impact on morbidity and mortality rates in patients aﬀected by chronic kidney disease
and mineral bone disorder (CKD-MBD). Eﬀects are manifested from the more advanced stages of CKD (stages 3-4), particularly
in patients undergoing dialysis (CKD5D). In recent years, a large number of therapeutic options have been successfully used in
the treatment of secondary hyperparathyroidism (SHPT),despite eliciting less markedeﬀects onnonbonecalciﬁcationsassociated
withCKD-MBD. InadditiontotheuseofVitaminDandanalogues,morerecentlytreatment withcalcimimeticdrugshasalsobeen
undertaken. The present paper aims to analyze comparative and eﬃcacy studies undertaken to assess particularly the impact on
morbidityandmortalityrates ofnon-calciumphosphatebinders.Moreover,themechanismofactionunderlying the depositingof
calciumandphosphatealongbloodvesselwalls,irrespective ofthespeciﬁccontributionprovidedinreducing thetypicalphosphate
levels observed in CKD largely at more advanced stages of the disease, will be investigated. The aim of this paper therefore is to
evaluate which phosphate binders are characterised by the above action and the mechanisms through which these are manifested.
1.Introduction
Over the last 10 years, it has become increasingly apparent
that chronic kidney disease-mineral and bone disorder
(CKD-MBD) is associated to extra-skeletal manifestations,
particularly cardiovascular calciﬁcations in patients at the
more advanced stages of CKD. The following manifestations
have been observed: calciﬁcations of the aorta, the carotid
and the coronary arteries resulting in a reduced elasticity,
diameter, compliance, and distensibility. The disease is
not conﬁned to central blood vessels but also involves
the iliac-femoral axis and all arteries in the limbs, thus
producing a high impact on the quality of life, morbidity
and mortality of these patients [1–3]. An additional element
implicated in the morbidity and mortality of patients is
represented by the manifestation of calciﬁcations on the
endothelium of heart valves, in particular the mitral and
aortic valves [4]. A fundamental impetus in the study of
compression exerted by calcium deposits in the vessels was
provided by Raggi using highly advanced procedures such
as electron-beam computed tomography (EBCT), partic-
ularly to assess the involvement of coronary arteries [5].
Hyperphosphatemia is one of the main features of chronic
kidney disease-mineral and bone disorder (CKD-MBD). An
excess of phosphorus represents an independent risk factor
for cardiovascular morbidity and mortality in patients with
advanced CKD. Options available for use in the treatment of
hyperphosphatemia are severecontrol ofdietary phosphorus
intake [6], use of phosphate binders [7], and optimized
phosphorus output choosing high-eﬃciency dialysis as high
ﬂux-methodology [8–10]. Phosphate binders are used for
theirbindingactionstoreducetheabsorptionofphosphorus
by the gastrointestinal lumen.
Calciumphosphate binders such as calcium carbonate or
acetate are still widely used today. Evidence of an increased
risk of onset and progression of nonbone, particularly
vascular, calciﬁcations has led to the use of caution by
nephrologists, in spite of the markedly lower costs compared
to the price of the new non-calcium. The concept whereby
the at times excessive use of calcium-containing phosphate2 International Journal of Nephrology
binders would appear to be widely accepted, together with
the notion that in the future patients at the CKD5D stage
should be treated to return dialysate calcium concentration
to values below 1.5mmol/L [11]. The latter is particularly
important in patients undergoing peritoneal dialysis who are
exposed at length to transfers of mass and therefore a long-
lasting, harmful positive calcium balance.
To brieﬂy mention a few literature references cited in
a recent review by Mason and Shepler [12], the authors
underlined how seven of the nine studies reported a statis-
tically signiﬁcant increase in vascular calciﬁcationin patients
takingcalcium-containingphosphatebindersasmeasuredby
coronary artery calciﬁcation scores and aortic calciﬁcation
scores. Over the last year, the therapeutic target has changed;
indeed, CKD-MBD may be characterized by SHPT, thus
resulting in an increased risk when administering calcium-
based phosphate binders in the presence of hypo-adinamic
bone disease both in incident dialysis patients, in prevalently
older subjects, or those with a dialytic age of more than
two years [13]. This abnormal mineral metabolism currently
represents a major therapeutic challenge focusing mainly
on the issue of vascular calciﬁcations even in the earlier
stages of CKD [14]. Recent evidence has suggested that non-
calcium-based phosphate binding agents such as sevelamer
hydrochloride, sevelamer carbonate, and lanthanum car-
bonate may attenuate cardiovascular calciﬁcationscompared
with calcium-based phosphate binders. Furthermore, as
will be discussed subsequently, these agents feature several
additional pleiotropic eﬀects including the action exerted on
lipid metabolism and systemic inﬂammatory response.
The aim of the present review is not to illustrate the
speciﬁc actions produced by calcium-based binders and
other drugs, including calcimimetic agents, but rather to
focus on the direct and indirect mechanism of action of non-
calcium phosphate binders. In doing so, emphasis will be
placedalmostexclusivelytorecentstudiesundertakenandno
reference was made to morbidity and mortality rates, which
are beyond the scope of this paper.
2.Phosphate andActionsProducedon
VascularCalciﬁcations
The recently published KDIGO guidelines, as well as the
previous KDOQI version, underline the importance of
maintaining phosphate levels within the normal range from
the earliest stages of CKD. This recommendation is based
on the action exerted by elevated blood phosphate levels
in inducing parathyroid cell proliferation and SHPT [15],
resulting in an increase in the number of hospitalizations
and in mortality rates, bone fractures, and vascular calci-
ﬁcations. Hyperphosphatemia has been associated with a
poor outcome and mortality in CKD stage 5D and high
normal serum phosphorus levels; CKD patients have the
same problem until stage 3. Patients with CKD stages 4-5D
frequently feature high serum phosphorus levels linked to
the development of aspects of CKD-MBD, including SHPT,
reduced serum calcitriol levels, abnormal bone remodelling,
andsoft-tissuecalciﬁcations.Laboratory-based experimental
data suggest that hyperphosphatemia may directly cause or
exacerbate other aspects of CKD-MBD, speciﬁcally arterial
calciﬁcation.Beta-glycerophosphate,aphosphatedonor,and
uremic sera induce calciﬁcation and osteopontin expression
in bovine vascular smooth muscle (BVSM) cells [16]. In
vitro experiments have demonstrated how phosphate acts
directly on cultured vascular cells to produce an osteo-
chondrogenic phenotypic transformation associated to loss
of contractility, mineralization of the extracellular matrix
by means of a sodium-dependent phosphate cotransport,
expression of speciﬁc bone markers, and calciﬁcation of
matrix protein [17]; a state of microinﬂammation results
in a worsening of this mechanism [18]. It should also be
borne to mind that vascular calciﬁcation is characterized
by the deposition of Ca2+ and inorganic phosphate (Pi)
in the form of hydroxyapatite (HA) crystals within the
medial or neointimal layers of blood vessels. This can
involve induction of osteochondrogenic programs of gene
expression in vascular smooth muscle cells (VSMCs) [19].
The uremic sera-induced osteopontin expression in BVSMC
is partially mediated through alkaline phosphatase activity
and an Na/Pi cotransporter-dependent mechanism. The
association of coronary arteries, the descending aorta, and
the mitral annulus irrespective of the presence of other risk
factors has previously been demonstrated for the interme-
diate stages of CKD by ﬁndings obtained in the MESA
(Multi-Ethnic Study of Atherosclerosis) [20]. Recently, Sage
et al. showed that vascular calciﬁcations produced as a
result of uremic hyperphosphatemia are associated with
vascular cell expression of osteogenic genes, including bone
morphogenetic protein- (BMP-) 2 and osteopontin (OPN).
High inorganic phosphate levels in vitro stimulate the
osteogenic conversion of smooth muscle cells; however, the
mechanism governing this is not clear. We found that high-
phosphate medium increased the expression of BMP-2 and
OPN in mouse smooth muscle cells in culture. However, this
eﬀectwas lost in the presence ofthe mineralization inhibitor,
pyrophosphate, suggesting a contribution of calcium phos-
phate crystals. These ﬁndings prompt further research into
the potential of pyrophosphate as treatment for vascular
calciﬁcation in chronic kidney disease patients [21].
3.MethodsAppliedinLiteratureReview
Two hundred and thirty-seven published papers describing
a correlation between hyperphosphatemia in CKD and
vascular calciﬁcations were analyzed. Subsequently, papers
relating to a total of 9 randomized trials or featuring an
eﬀective study design were selected. All studies had focused
ontheuseofnon-calciumphosphatebindersasatherapeutic
option aimed at reducing nonbone, and prevalently vascular,
calciﬁcationsin apopulationof879 patients. The trials taken
into consideration are listed in Tables 1 and 2.
4.Discussion
In spite of the lack of evidence from randomized controlled
trials (RCTs) to demonstrate that a lowering of phosphorusInternational Journal of Nephrology 3
Table 1: A study analyzingthe eﬀect of non-calcium-based phosphate binders.
Reference Study Patient
population
Comparison Study design Results
Block et al. [15] RIND Incident HD Calcium (55) Sevelamer (54) Randomly assigned
Calcium binders resulted in more
increase in CACS versus sevelamer
at 18 months (P = .015); median
increase in CACS was 11 times
greater with calcium versus
sevelamer (P = .01)
Chertow et al. [24] TTG Prevalent HD Calcium (75) Sevelamer (66) Randomly assigned
Calcium binders with greater
percentage of CACS versus
sevelamer at 26 and 52wk
P = .02, P = .04
Qunibi et al. [31] CARE-2 Prevalent HD Calcium (58) Sevelamer (68)
Randomly assigned
with atorvastatinto
both binders or
52wk
Nonsigniﬁcative diﬀerences in
CACS between calcium and
sevelamer
Barreto et al. [32] BRiC Prevalent HD Calcium (18) Sevelamer (11) Randomly assigned
Nonsigniﬁcative diﬀerences in
CACS between calcium and
sevelamer
Boaz et al. [35] N/A Predialysis pts Calcium (28) Sevelamer (27)
Low-phosphorus
diet with both
binders
Increase in TCS with calcium to
baseline (P = . 001); NS with
sevelamer
Table 2: A study analyzingthe eﬀect of non-calcium-based phosphate binders.
Reference Study Patient
population
Comparison Study design Results
Chue et al. [51]N / A P r e v a l e n t H D Calcium
(13) Lanthanum (17) Randomly assigned
Lanthanum reduced progression
of aortic VC (P<.001) versus
calcium
Raggi et al. [25]N / A P r e v a l e n t H D Calcium
(130) Sevelamer (132) Observation at
52wk
Sevelamer arrested the progression
of valvular and vascular
calciﬁcation (P = .02) versus
calcium
Galassi et al. [28]N / A I n c i d e n t H D Calcium
(20ND, 25D)
Sevelamer
(13ND, 27D) Randomly assigned
Hemodialysis diabetic at 18
months,a greater progression of
CACS (P = .005) than with
sevelamer with iPTH ranges
suggestive of low bone turnover
Takei et al. [45]N / A P r e v a l e n t H D Calcium
(21) Sevelamer (21) Randomly assigned
Sevelamer suppresses progressive
aortic calciﬁcation more than with
calcium
Raggi et al. [34] SUMMER Prevalent HD Calcium
(130) Sevelamer (45) Cross-sectional
Less carotid and femoral intima
media thickness, minor levels of
LDL-cholesterol, higher iPTH
with sevelamer versus calcium
levels impacts clinical outcomes, it may be reasonable to
lower phosphorus in CKD patients with hyperphosphatemia
using phosphate binders. Limiting dietary phosphate intake
or increasing the frequency or duration of dialysis sessions
is not alone suﬃcient to lower phosphorus levels. Patient
compliance is therefore fundamental not only in limiting
dietary intake of phosphorus, but also in adhering to the
prescribed protocol of phosphate binder administration,
frequently linked to the number of pills the patient is
required to take and the degree of gastric tolerance of the
product prescribed.
There is insuﬃcient evidence that any speciﬁc phosphate
binder signiﬁcantly impacts patient-level outcomes. Thus,
the choice of phosphate binder should be selected on an
individual basis. Moreover, the lowering of phosphate levels
is becoming increasingly acknowledged as mandatory in
reducing the onset of nonbone, and in particular car-
diac and/or vascular, calciﬁcations that produce a marked4 International Journal of Nephrology
eﬀect on mortality rates in patients at various stages of
CKD.
Large epidemiological studies have consistently shown
the importance ofhyperphosphatemia as a predictorof mor-
talityinCKDstage5patientsreceivingdialysis.Experimental
data suggest a direct causal relationship between phosphorus
and several components of CKD-MBD, speciﬁcally SHTP
bone abnormalities and calcitriol deﬁciency. Mention is also
made of the negative interferences produced by a vitamin K
deﬁcit in patients undergoing dialysis, that may facilitate the
onsetofvascular calciﬁcations,particularly inpatients taking
dicumarol [22].
In the present paperwe will focusmainly on vascularcal-
ciﬁcations and how to personalize treatment with phosphate
binders in an attempt to reduce the presence of calciﬁcations
on blood vessel walls. The establishing of optimum calcium
levels which, if associated to hyperphosphatemia, may give
rise to vast and extensive areas of nonbone calciﬁcations is
of paramount importance. Non-calcium phosphate binders
available currently are aluminium hydroxide, ferric citrate,
magnesium carbonate, sevelamer HCl and sevelamer car-
bonate, and lanthanum carbonate. This paper will focus
mainly on the latter two due to the lack of controlled,
prospective, or retrospective trials capable of demonstrating
af a v o u r a b l ea c t i o no fa l u m i n i u mh y d r o x i d e( t h eu s eo f
which isnotadvised inthelongterm),magnesium carbonate
and ferric citrate on vascular calciﬁcations. Furthermore,
studiesperformed on the dialysispopulationwith niacin and
nicotinamide have shown signiﬁcant phosphate reduction
with lowering of the calcium-phosphorus product. However,
to date, no published reports or trials have been made
available that demonstrate activity of this phosphate binder
on vascular calciﬁcations.
5.SevelamerfromCKDStage5D:
EffectsandComparisonwith
Calcium-BasedPhosphate Binders
Asreported in multiple publications,numerous trials under-
takento compare sevelamer HClwith calcium-based binders
have assessed the impact of phosphate-binder therapy on
arterial calciﬁcation, assessed using computerized tomog-
raphy imaging techniques. In two subsequent papers, the
ﬁrst reporting on200 patientsrandomized toadministration
of calcium acetate or sevelamer over a one-year period to
correct hyperphosphatemia, and the second paper studying
108 hemodialysis patients likewise randomized to calcium
acetate or sevelamer and followed for one year, Chertow
demonstrated how calcium treatment led to progressive
coronary artery and aortic calciﬁcation as determined
by sequential EBCT, while the use of the non-calcium-
containing binder sevelamer was devoid of a similar eﬀect
[23, 24]. A further paper examined the eﬀect of these
two oral phosphate-binders on valvular calciﬁcation in
132 hemodialysis patients, concluding that after a one-year
observation period, sevelamer had checked the progression
of vascular and valvular calciﬁcations in almost 50% of
patients [25].
Another report suggested that patients randomized to
receive calcium salts, compared with those randomized
to sevelamer HCl, experienced greater trabecular (but not
cortical) bone loss on the basis of changes in thoracic bone
mineral density (BMD) on EBCT scans in a subset of 132
patients in whom the necessary imaging was available [26].
More recent paper have expressed some doubt as to the
eﬀective harmfulness of the use of calcium-based phosphate
binders in the treatment of hyperphosphatemia and vascular
calciﬁcations, which has inevitably led to a rise in the use
of sevelamer [27]. An interesting study [28] examining the
clinical outcomes in a smaller group of 109 incident HD
patients (patients new to dialysis, 64 diabetics and 45 non
diabetics) randomized to either sevelamer HCl or calcium-
based binder followed up patients for a period of 18 months.
Patients received baseline, six, 12, and 18 months EBCT
scans. The study found that diabetic patients who used
calcium-based phosphate binders experienced more rapid
and more severe progression of coronary artery calciﬁcation
than those using sevelamer.
Diabetic patients treated with calcium-based binders
showed a signiﬁcantly greater coronary artery calcium
score (CACS) progression than sevelamer-treated patients
(median increase 177 versus 27; P = .05). During fol-
lowup, diabetic patients receiving calcium-based binders
were signiﬁcantly more likely to develop serum iPTH values
<16pmol/L than diabetic patients treated with sevelamer
(33% versus 6%, P = .005) and had a lower mean iPTH
level (24 ± 16 versus 31 ± 14pmol/L; P = .038). No
data on cardiovascular events other than death, fractures,
or parathyroidectomy rates were available from either of
these studies, making it impossible to draw conclusions on
the impact of using sevelamer HCl instead of a calcium-
based phosphate binder on such outcomes. In addition, no
studies have examined the eﬀects of lanthanum carbonate or
indeed any other phosphate binder (including calcium- and
aluminium-based compounds) on patient-level outcomes.
T h el a r g e s to ft h e s es t u d i e s , the Dialysis Clinical Out-
comes Revisited (DCOR) study, [29] randomized 2103
prevalent CKD stage 5D patients to either sevelamer HCl
or a calcium-based phosphate binder (70% calcium acetate
or 30% calcium carbonate). The trial was designed to
evaluate all-cause mortality; more patients discontinued
because of adverse events (AEs) in the sevelamer-HCl arm
(8 versus 5%), but types of events and event rates were not
comprehensively reported. The study was extended because
the mortality rate in the control group was lower than
expected. Only 1068 patients completed the study, and there
were no diﬀerences in all-cause or cause-speciﬁc mortality
rates when comparing sevelamer HCl (mortality rate 15.0
per 100 patient-years) with calcium-treated patients (16.1
per 100 patient-years). There were also no diﬀerences in
cardiovascular mortality and hospitalization on the basis of
datafromcasereport forms.Apossiblebiasresultedfromthe
limited(90days)followupofdiscontinuedpatients,aswellas
a lack of documentation of baseline biochemical parameters
and AEs.
A secondary analysis of the DCOR study [30]o no v e r -
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morbidity, or ﬁrst or cause-speciﬁc hospitalization (sec-
ondary outcomes) reported how the study had not been
well-balanced due to the presence of major atherosclerotic
cardiovascularcalciﬁcationsinpatientstreatedwithcalcium-
based phosphate binders. This study showed a beneﬁcial
eﬀect of sevelamer HCl on the secondary outcomes of
multiple all-cause hospitalizations and on the number
of days of hospitalization. Furthermore, hospitalizations
from CVD as ascertained from the administrative data did
not diﬀer, lending no support to the study’s hypothesis
that sevelamer HCl reduces cardiovascular disease (CVD)
morbidity. The analysis by Peter et al. using claims data
described a higher rate of hospitalization in a smaller group
of patients with a shorter duration of follow-up than that
reported by Suki et al., as a result of the fact that the
denominator for hospitalization rates did not include days
spent in hospital. Thus, although both analyses showed a
trend toward lower hospitalization rates, the fact that the
diﬀerencebetween patientsallocated to diﬀerentbinderswas
of statistical signiﬁcance in the analysis by Peter et al. was not
considered robust.
In the CARE 2 study [31], chronic HD patients from
the United States were randomized to receive either calcium
acetate or sevelamer HCl. Two hundred and eighty-seven
patients in both groups received atorvastatin to achieve
a low-density lipoprotein cholesterol goal of 70mg/dL
(1.81mmol/L). The study was designed to assess noninfe-
riority, evaluating CAC using EBCT at 6 and 12 months
after randomization. Before 1 year, 30% of the patients
in the sevelamer arm and 43% in the calcium acetate
arm dropped out. Despite achieving comparable levels of
serumcholesterol, no diﬀerencein theprogression ofarterial
calciﬁcation was noted when comparing the two treatment
arms (calcium acetate and sevelamer HCl groups, resp.,
P = .90). The weakness of this study is constituted by the
high presence of pre-existing calciﬁcations in the patients
investigated.
In a prospective study undertaken by Barreto et al.
[32], 101 hemodialysis patients were randomized for each
phosphate binder and submitted to multislice coronary and
bone biopsies at entry and 12 months to compare the eﬀects
of calcium acetate and sevelamer on coronary calciﬁcation
(CAC) and bone histology; there was no diﬀerence in CAC
progression or changes in bone remodelling between the
calcium and the sevelamer groups; however, this study
was hampered by small sample size, use of low dialysate
calcium concentrations (1.25mmol/L), and no limits in
the use of aluminium hydroxide, which likely aﬀected the
progression of vascular calciﬁcations. Similar conclusionson
CACS and mortality rates were reached by a recent meta-
analysis of 2873 patients [33]. A recent paper performed
by Raggi et al. [34] of a ten-year period of observation
provided encouraging results for the use of sevelamer due
to the improvements produced in vascular calciﬁcations,
bone physiology, and a potential positive trend in mortality
rates for hemodialysis patients. Recently, Boaz et al. [35]
studied a group of 45 hemodialysis patients treated with
sevelamer and 130 untreated subjects; patients receiving
sevelamer had signiﬁcantly lower carotid intima media
thickness and lower low-density lipoprotein cholesterol
levels.
Scarce literature reports are available that relate to the
predialysis stage of CKD. Relatively few papers have been
published, including an Italian study involving 90 binder-
naive Italian patients with CKD stages 3–5 who were not
receiving dialysis. Russo et al. [36] randomized patients (30
per group) into either a low-phosphate diet alone group,
a low-phosphate diet in combination with ﬁxed doses of
calcium carbonate (2g/d) group, or a low-phosphate diet
in combination with sevelamer HCl (1600mg/d) group and
followed up these individuals for 2 years. Coronary artery
calciﬁcation (CAC) was the primary end point of the study;
in the 84 patients who completed the study, the ﬁnal CAC
scores were greater than the initial scores in those receiving
diet alone (P<. 001) or diet in combination with calcium
carbonate (P<. 001), whereas there was no progression of
calciﬁcation in the diet-plus-sevelamer-HCl-treated group.
6.Mechanisms ofAction
The mechanism through which non-calcium phosphate
binders exert their action and slow down progression of
vascular calciﬁcations is still unclear and remains to be
clariﬁed. However, the RIND study, evaluating progression
of coronary artery calciﬁcation in incident hemodialysis
patients, demonstrated that vascular calciﬁcation processes
manifest in predialysis stages in the majority of patients,
which maywellbelinkedtoderangedcalciumandphosphate
homeostasis. Novel insights into the pathophysiology of
calcium and phosphate handling, especially the discovery
of the phosphatonin FGF23, suggest that a more complex
assessment of phosphate balance is warranted. This assess-
ment should include measurements of fractional phosphate
excretion and phosphatonin levels to objectively judge and
eﬀectively correct phosphate overload [37].
New markers, such as FGF-23, have been identiﬁed as
inducers of vascular calciﬁcation and cardiovascular disease
in CKD. Therefore, the use of calcium-free phosphate
binders may reduce the risk of cardiovascular disease by
reducing both serum phosphate and FGF-23 levels [38].
Recent ﬁndings have provided evidence of a direct action
of non-calcium phosphate binders on the progression of
vascular calciﬁcations. Data published to date on the use
of non-calcium phosphate binders such as sevelamer and
lanthanum carbonate recommend the administration of
these drugs from the initial stages of CKD in association
with a dietary intake of phosphorous in order to prevent an
increase in FGF-23 and the action produced by the later on
vascular calciﬁcations [39, 40].
In view of the large number of reports published on
the potential actions exerted by sevelamer in halting the
progression of vascular calciﬁcations, this binder should
be dealt with separately [41–45]; it has accordingly been
demonstrated that sevelamer is capable of lowering mean
levels of HDL cholesterol, apolipoprotein B, and homo-
cysteine. Furthermore, a decrease in the expression of the6 International Journal of Nephrology
nitrotyrosine marker of inﬂammatory stress by atheroscle-
rotic plaques in the aorta and stabilization of the plaques, a
decrease in CRP, and a reduced gastrointestinal absorption
of several uremic toxins have also been reported [46].
In addition to the eﬀects produced on FGF23, it is of
considerableinterestthatsevelamerhasbeenfoundtoreduce
serum Fetuin A levels, known to exert a cardiovascular
protective action [47].
A carbonated form of sevelamer featuring a similar
eﬃcacy in control of hyperphosphatemia and which does
not worsen metabolic acidosis, as occurs with the HCl
preparation, has recently been introduced onto the market
[48, 49]. At the current time, no conclusivedata are available
from controlled trials on the action of sevelamer carbonate.
It does however seem feasible that this product may possess
a similar eﬃcacy in the treatment of vascular calciﬁcationsin
patientsatallstagesofCKD[50].Trialshaverecentlybeenset
uptodemonstratethepotentialpositiveeﬀectsoflanthanum
carbonate on myocardial function and blood vessel elasticity
and calciﬁcations [51].
7.LanthanumCarbonate
A positive action of lanthanum carbonate on vascular
calciﬁcations had already been hypothesized [52]; although
relatively few papers have been published to date to this
regard, indications are provided of a positive eﬀect of
lanthanum carbonate on the progression of vascular calci-
ﬁcations. One of the most recent papers [53]r e p o r t e do nt h e
ﬁndings of a pilot randomized controlled trial undertaken
to determine the eﬀect of lanthanum carbonate (LC) on
vascular calciﬁcation (VC). Forty-ﬁve HD patients were
randomized to either LC or calcium carbonate. The primary
outcome of changes to aortic VC after 18 months included
superﬁcial femoral artery (SFA) VC, bone mineral density
(BMD) of lumbar spine, and serum markers of mineral
metabolism. At baseline, 6-month computed tomography
was performed to measure VC and BMD. A random and
at 18-month eﬀect linear regression model was performed
to assess diﬀerences. Results. Thirty patients completed the
study; indeed, the small sample size and loss to followup
were one of the major limitations to this study. Lanthanum
carbonate was associated with the reduced progression of
aortic calciﬁcation compared with calcium carbonate in HD
patients over 18 months.
8.MagnesiumCarbonate
For the sake of thoroughness, this paper on the action of
non-calcium phosphate binders will conclude with a brief
analysis of magnesium carbonate and another non-calcium
binder was used only rarely. Indeed, an inverse correla-
tion between magnesium levels and the extent of vascular
calciﬁcations was demonstrated many years ago (studies
from 1974 to 2004) in one study undertaken to evaluate
peritoneal dialysis and three conducted on hemodialysis
patients; the latter trials have been amply analyzed in a
review by Wei et al. in 2006 [54]. Observational data suggest
that elevated magnesium levels in dialysis patients may
prevent vascular calciﬁcation, and in vitro magnesium can
prevent hydroxyapatite crystal growth. However, the eﬀects
of magnesium on vascular calciﬁcation and bone mineral
density have not been studied prospectively. In a preliminary
study, Spiegel [55] hypothesized that magnesium carbonate
was capable of interrupting the progression of vascular
calciﬁcations; in a recent open-label pilot study, the same
Author studied seven chronic hemodialysis patients to
evaluate the eﬀects of a magnesium-based phosphate binder
on coronary artery calciﬁcation (CAC) scores and vertebral
bone mineral density [56]. Magnesium carbonate/calcium
carbonateadministeredastheprincipalphosphatebinderfor
a period of 18 months and changes in CACand V-BMD were
measured at baseline, 6, 12, and 18 months. Electron beam
computed tomography results demonstrated a small and not
statistically signiﬁcant increase in absolute CAC scores, no
signiﬁcant change in median percent change, and a small
insigniﬁcant change in V-BMD.
To conclude, a large number of reports present in
literature recommend that serum phosphate levels be closely
monitored, whilst at the same time not overlooking impor-
tant aspects such as eliciting a decrease in the onset and
progression of vascular calciﬁcations that produce a marked
eﬀect on the morbidity and mortality rates of CKD patients
at all stages. The tendency is to reduce calcium intake
both through dialysis and by administration of non-calcium
phosphate binders that have proved eﬀective in controlling
hyperphosphatemia but which also feature pharmacological
characteristics capable of producing a direct decrease in
calciﬁcations to the vascular endothelium. In spite of the
large body of evidence provided in literature, further ran-
domized, prospective studies should be undertaken with the
speciﬁc aim of evaluating the incident population to provide
further conﬁrmation and optimization of the beneﬁcial
eﬀects reported to date.
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